πŸ‡ΊπŸ‡Έ FDA
Patent

US 7622610

Crystalline ACAT inhibitor

granted A61KA61K31/16A61P

Quick answer

US patent 7622610 (Crystalline ACAT inhibitor) held by Graceway Pharmaceuticals. LLC expires Mon Nov 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Graceway Pharmaceuticals. LLC
Grant date
Tue Nov 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/16, A61P, A61P17/00, A61P17/08